Full-Time

VP – Global Medical Affairs

Oncology

Updated on 3/14/2025

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

Expert

Cambridge, MA, USA

70% in-office work required.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • MD or non-US equivalent of MD degree and/or PhD.
  • 10+ years of experience working in biotech/pharma industry.
  • 10+ years of relevant job experience.
  • Knowledge and experience with FDA, EMA, ICH, and GCP guidelines.
  • Prior interactions with public health agencies, medical and scientific societies.
Responsibilities
  • Accountable for the leadership, development and execution of Medical Affairs strategy for the oncology franchise.
  • Lead the Medical Affairs strategy for the individualized neoantigen therapy (INT) program in close collaboration with Moderna’s external partner, ensuring alignment and excellence in execution.
  • Provide scientific and functional leadership to the Medical Affairs and Commercial teams.
  • Serve as a key partner with Commercial in terms of market-building activities, including building of Health Economics and Outcomes Research (HEOR) models.
  • Develop and lead Key Opinion Leader Outreach, publication strategy and planning, CME education, symposia, and congress planning.
  • Establish policies and procedures for key Medical Affairs activities, ensuring compliance with the principles of Scientific Engagement, including leading discussions around compassionate use programs.
  • Actively contribute to the development of Target Product Profiles, contributing the voice of the medical professional to the development of these assets.
  • Contribute to the selection of vendors and design of educational materials.
  • Accountable for copy approval of external materials.
  • Accountable for the development and approval of key Medical Information documents for licensed products in the oncology franchise.
  • Represent Moderna as the key liaison with public health bodies and medical and scientific societies worldwide.
  • Lead the Medical strategy for Advisory Board meetings for the oncology franchise.
  • Partner with Legal and Compliance to ensure Medical Affairs activities are conducted according to Moderna’s policies and procedures, and in a manner compliant with all external laws and regulations.
  • Develop and maintain strong, collaborative relationships with the broader Moderna organization.
Desired Qualifications
  • Extensive experience in oncology or a related therapeutic area.
  • Proven ability to plan and execute Medical Strategies.
  • Ability to thrive in a fast-paced environment.
  • Attention to detail, internal drive to generate high-quality work, and sense of passion and urgency to achieve team and program goals.
  • Excellent analytical, problem-solving and strategic planning skills.
  • Strong interpersonal skills commensurate with the need to work closely with CROs, investigators, consultants, and team members across functions.
  • Exceptional written and oral communication skills to meet the needs of varied audiences.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial molecule that provides instructions for cells to produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially transform how drugs are discovered, developed, and manufactured. Unlike traditional methods that often rely on proteins or antibodies, Moderna's use of mRNA allows for a more direct way to instruct cells to produce therapeutic proteins. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create effective treatments for a range of diseases.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna plans to launch a cancer vaccine with Merck by 2027.
  • The company secured a $590 million contract for bird flu vaccine development.
  • Moderna's mRNA COVID-19 vaccine supply agreement with the EU spans four years.

What critics are saying

  • Moderna faces a high-profile patent lawsuit with Pfizer and BioNTech.
  • The company reported significant net losses in 2024, impacting financial stability.
  • Regulatory scrutiny may delay product approvals, affecting future growth.

What makes Moderna unique

  • Moderna is pioneering mRNA as a new class of medicines.
  • The company focuses on mRNA technology for personalized medicine and vaccines.
  • Moderna's mRNA platform enables rapid development of therapeutics and vaccines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
Assure Test
Mar 7th, 2025
Pfizer & BioNTech vs. Moderna: COVID-19 Vaccine Patent Lawsuit

The high-profile lawsuit between Pfizer, BioNTech, and Moderna over mRNA COVID-19 vaccine patents remains one of the most closely watched cases in 2025.

Bloomberg
Mar 5th, 2025
Moderna Eyes 2027 Launch for Cancer Vaccine Developed With Merck

Moderna Inc. expects to launch a personalized cancer vaccine that it's developing with Merck & Co. by 2027, one of its top executives said.

The Wall Street Journal
Feb 27th, 2025
Moderna Shares Fall After Reports of HHS Review of Bird Flu Vaccine Contract

Moderna was awarded the contract from the U.S. Department of Health and Human Services in January during the Biden administration to accelerate development of its mRNA-based vaccine, and as part of an effort to address growing concerns of a bird flu pandemic in humans.

Financial Modeling Prep
Feb 14th, 2025
Moderna, Inc. (NASDAQ:MRNA) Faces Challenges and Opportunities in Biotech Sector

Moderna is developing new products, including a next-generation COVID vaccine, with a revenue forecast between $1.5 billion and $2.5 billion for 2025.

PharmiWeb
Feb 14th, 2025
Moderna Reports Fourth Quarter And Fiscal Year 2024 Financial Results And Provides Business Updates

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizingReports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28)Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billionSubmitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccineCAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024."We have made progress in 2024 across our late-stage pipeline and cost reduction efforts. Our team successfully filed three Biologics License Applications in the final months of the year and reduced our costs by 27 percent compared to 2023," said Stéphane Bancel, Chief Executive Officer of Moderna. "In 2025, we remain focused on driving sales, delivering up to 10 product approvals through 2027, and expanding cost efficiencies across our business. By the end of 2025, we aim to remove nearly $1 billion in costs. With strong momentum in our late-stage pipeline, we anticipate multiple approvals starting this year, along with key Phase 3 readouts that will support our long-term growth."Recent progress includes:Commercial UpdatesModerna is entering 2025 with two approved products, Spikevax® and mRESVIA®.COVID-19: The Company reported $923 million in Spikevax® sales in the fourth quarter of 2024, which includes $244 million of U.S